Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer CellsYAMADA, Tadaaki; TAKEUCHI, Shinji; UENAKA, Toshimitsu et al.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3592-3602, issn 1078-0432, 11 p.Article

EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC InhibitionNAKAGAWA, Takayuki; TAKEUCHI, Shinji; YANO, Seiji et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 8, pp 2428-2434, issn 0008-5472, 7 p.Article

Rebiopsy of Non―Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: Comparison Between T790M Mutation-Positive and Mutation-Negative PopulationsHATA, Akito; KATAKAMI, Nobuyuki; MATSUMOTO, Takeshi et al.Cancer. 2013, Vol 119, Num 24, pp 4325-4332, issn 0008-543X, 8 p.Article

Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancerHATA, Akito; KATAKAMI, Nobuyuki; NISHIMURA, Takashi et al.Lung cancer. 2011, Vol 72, Num 2, pp 224-228, issn 0169-5002, 5 p.Article

The novel phosphoinositide 3-kinase―mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorSANO, Takako; TAKEUCHI, Shinji; NAKAGAWA, Takayuki et al.International journal of cancer (Print). 2013, Vol 133, Num 2, pp 505-513, issn 0020-7136, 9 p.Article

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selectionHATA, Akito; KATAKAMI, Nobuyuki; NISHIYAMA, Akihiro et al.Lung cancer. 2011, Vol 74, Num 2, pp 268-273, issn 0169-5002, 6 p.Article